TSUNEAKI YOSHINAGA

Dr. TSUNEAKI YOSHINAGA

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 April 2020 in Rheumatology International
Verified
Journal Article
Closed access
PDF file
DKDai Kishida
Dai Kishida
NSNoriko Sakaguchi
Noriko Sakaguchi
KUKen-Ichi Ueno
Ken-Ichi Ueno
SUSatoru Ushiyama
Satoru Ushiyama
TITakanori Ichikawa
Takanori Ichikawa
YSYoshiki Sekijima
Yoshiki Sekijima

Verified
Journal Article
Open access
PDF file
MYMasahide Yazaki
Masahide Yazaki
TYTSUNEAKI YOSHINAGA
TSUNEAKI YOSHINAGA
YSYoshiki Sekijima
Yoshiki Sekijima
F亀Fuyuki 亀谷
Fuyuki 亀谷
NONobuo Okumura
Nobuo Okumura
Hereditary fibrinogen Aα-chain amyloidosis (Aα-chain amyloidosis) is a type of autosomal dominant systemic amyloidosis caused by mutations in fibrinogen Aα-chain gene (FGA). Patients with Aα-chain amyloidosis have been mainly reported in Western countries but have been rarely reported in Asia, with only five patients with Aα-chain amyloidosis being reported in Korea, China, and Japan. Clinically, the most prominent manifestation in Asian patients with Aα-chain amyloidosis is progressive nephropathy caused by excessive amyloid deposition in the glomeruli, which is similar to that observed in patients with Aα-chain amyloidosis in Western countries. In molecular features in Asian Aα-chain amyloidosis, the most common variant, E526V, was found in only one Chinese kindred, and other four kindred each had a different variant, which have not been identified in other countries. These variants are located in the C-terminal region (amino acid residues 517–555) of mature Aα-chain, which was similar to that observed in patients with Aα-chain amyloidosis in other countries. The precise number of Asian patients with Aα-chain amyloidosis is unclear. However, patients with Aα-chain amyloidosis do exist in Asian countries, and the majority of these patients may be diagnosed with other types of systemic amyloidosis.

Verified
Journal Article
Open access
PDF file
SIShojiro Ichimata
Shojiro Ichimata
YHYukiko Hata
Yukiko Hata
TYTSUNEAKI YOSHINAGA
TSUNEAKI YOSHINAGA
NKNagaaki Katoh
Nagaaki Katoh
F亀Fuyuki 亀谷
Fuyuki 亀谷
NNNaoki Nishida
Naoki Nishida
This study aimed to elucidate the similarities and differences between amyloid-forming corpora amylacea (CA) in the prostate and lung, examine the nature of CAs in cystic tumors of the atrioventricular node (CTAVN), and clarify the distinctions between amyloid-forming CA and spheroid-type amyloid deposition. We conducted proteomics analyses using liquid chromatography–tandem mass spectrometry with laser microdissection and immunohistochemistry to validate the characteristics of CAs in the lung and prostate. Our findings revealed that the CAs in these organs primarily consisted of common proteins (β2-microglobulin and lysozyme) and locally produced proteins. Moreover, we observed a discrepancy between the histopathological and proteomic analysis results in CTAVN-associated CAs. In addition, while the histopathological appearance of the amyloid-forming CAs and spheroid-type amyloid deposits were nearly identical, the latter deposition lacked β2-microglobulin and lysozyme and exhibited evident destruction of the surrounding tissue. A literature review further supported these findings. These results suggest that amyloid-forming CAs in the lung and prostate are formed through a shared mechanism, serving as waste containers (wasteosomes) and/or storage for excess proteins (functional amyloids). In contrast, we hypothesize that while amyloid-forming CA and spheroid-type amyloid deposits are formed, in part, through common mechanisms, the latter are pathological.

Verified
Journal Article
Open access
PDF file
TYTSUNEAKI YOSHINAGA
TSUNEAKI YOSHINAGA
YYYuuki Yoshioka
Yuuki Yoshioka
FTFelix J. Tsai
Felix J. Tsai
LNLuke Nelson
Luke Nelson
MCMing Cheng
Ming Cheng
YSYoshiki Sekijima
Yoshiki Sekijima
Over 150 transthyretin (TTR) mutations have been identified in hereditary transthyretin (ATTRv) amyloidosis, and new TTR variants have recently emerged. However, the pathogenicity of several new variants remains unclear, making it important to elucidate the differences between amyloidogenic and wild-type TTR. In this study, we report a novel TTR variant (V121A) identified in two unrelated amyloidosis patients aged > 60 years who developed cardiomyopathy. We evaluated the detailed biochemical features of this TTR variant to confirm its amyloidogenicity using plasma samples from these patients and recombinant TTR proteins. While the V121A TTR variant has a similar ability to assemble into a tetramer as wild-type TTR, it aggregates more readily over a wide potential hydrogen range than wild-type TTR. Additionally, the V121A variant is highly prone to dissociation and resistant to binding with known TTR tetramer stabilizers. Clinical and biochemical data suggest that this novel variant is clearly pathogenic, is highly prone to dissociation and aggregation, and is associated with the development of late-onset amyloid cardiomyopathy. Interestingly, amyloid fibril formation due to this variant may not be affected by known TTR stabilizers.

1 January 2010 in Rinsho Shinkeigaku
Verified
Journal Article
Open access
PDF file
TYTSUNEAKI YOSHINAGA
TSUNEAKI YOSHINAGA
DMDaigo Miyazaki
Daigo Miyazaki
KFKazuhiro Fukushima
Kazuhiro Fukushima
YSYasuhiro Shimojima
Yasuhiro Shimojima
MMMasayuki Matsuda
Masayuki Matsuda
SIShu-ichi Ikeda
Shu-ichi Ikeda
症例は73歳男性である.68歳時より四肢近位筋の筋力低下,首下がり,体重減少,皮膚硬化が緩徐に進行し,当院を受診した.顔面,頸部,上肢の高度な皮膚硬化,頸部,舌,四肢近位筋優位の全身性筋萎縮をみとめた.線維束性収縮はみとめず,深部腱反射は低下.病的反射は陰性.感覚障害はみとめなかった.血清CK値は321IU/l と軽度に上昇し,抗核抗体は陽性(5,120倍,核小体型).針筋電図にて全被検筋に筋原性変化が示され,全身性強皮症に全身性強皮症関連ミオパチーが合併したものと診断した.本症で首下がりや舌萎縮をふくむ高度の全身性筋萎縮を呈する例はまれであるが,筋萎縮症例の鑑別において留意すべき疾患と考えられた.

6 March 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
SIShojiro Ichimata
Shojiro Ichimata
YHYukiko Hata
Yukiko Hata
TYTSUNEAKI YOSHINAGA
TSUNEAKI YOSHINAGA
NKNagaaki Katoh
Nagaaki Katoh
F亀Fuyuki 亀谷
Fuyuki 亀谷
NNNaoki Nishida
Naoki Nishida
This study aimed to elucidate the similarities and differences between amyloid-forming corpora amylacea (CA) in the prostate and lung, examine the nature of CAs in cystic tumors of the atrioventricular node (CTAVN), and clarify the distinctions between amyloid-forming CA and spheroid-type amyloid deposition. We conducted proteomics analyses using liquid chromatography–tandem mass spectrometry with laser microdissection and immunohistochemistry to validate the characteristics of CAs in the lung and prostate. Our findings revealed that CAs in these organs primarily consist of common proteins (β2-microglobulin and lysozyme) and locally produced proteins. Moreover, we observed a discrepancy between the histopathological and proteomic analysis results in CTAVN-associated CAs. In addition, while the histopathological appearance of amyloid-forming CAs and spheroid-type amyloid deposits were nearly identical, the latter deposition lacked β2-microglobulin and lysozyme, and exhibited evident destruction of surrounding tissue. A literature review further supported these findings. These results suggest that amyloid-forming CAs in the lung and prostate are formed through a shared mechanism, serving as waste containers (wasteosomes) and/or storage for excess proteins (functional amyloids). In contrast, we hypothesize that while amyloid-forming CA and spheroid-type amyloid deposits are formed, in part, through common mechanisms, the latter are pathological.